Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

al of 1262 patients with type 2 diabetes participated in two double-blind, placebo-controlled studies, one of 18-week and another of 24-week duration, to evaluate the efficacy and safety of JANUVIA monotherapy. In both monotherapy studies, patients currently on an antihyperglycemic agent discontinued the agent, and underwent a diet, exercise, and drug wash-out period of about 7 weeks. Patients with inadequate glycemic control (A1C 7% to 10%) after the wash-out period were randomized after completing a 2-week single-blind placebo run-in period; patients not currently on antihyperglycemic agents (off therapy for at least 8 weeks) with inadequate glycemic control (A1C 7% to 10%) were randomized after completing the 2-week single-blind placebo run-in period. In the 18-week study, 521 patients were randomized to placebo, JANUVIA 100 mg, or JANUVIA 200 mg, and in the 24-week study 741 patients were randomized to placebo, JANUVIA 100 mg, or JANUVIA 200 mg. Patients who failed to meet specific glycemic goals during the studies were treated with metformin rescue, added on to placebo or JANUVIA. Treatment with JANUVIA at 100 mg daily provided significant improvements in A1C, FPG, and 2-hour PPG compared to placebo (Table 2). In the 18-week study, 9% of patients receiving JANUVIA 100 mg and 17% who received placebo required rescue therapy. In the 24-week study, 9% of patients receiving JANUVIA 100 mg and 21% of patients receiving placebo required rescue therapy. The improvement in A1C was not affected by gender, age, race, or baseline BMI. As is typical for trials of agents to treat type 2 diabetes, mean response to JANUVIA in A1C lowering appears to be related to the degree of A1C elevation at baseline. Overall, the 200 mg daily dose did not provide greater glycemic efficacy than the 100 mg daily dose. The effect of JANUVIA on lipid endpoints was similar to placebo. Body weight did not increase from baseline with JANUVIA therapy in either stu
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:5/1/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ) ... and long-term growth strategies at a meeting with the ... . President and Chief Executive Officer Mike ... has to bring forward meaningful innovation to transform patient ... shareholder value. "We are focused on ...
(Date:5/1/2015)... , May 1, 2015  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... results for the third quarter fiscal year 2015 ... scheduled a conference call that same day, Thursday, ...
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) reported ... detailed analyses supporting the dosing,regimen in NTI,s two ... stroke. The company also provided information as to ... be successful in treating,ischemic stroke than previous Phase ...
... May 14 The Quigley,Corporation (Nasdaq: QGLY ... its wholly owned subsidiary, Quigley Pharma Inc., which ... of its compound,QR448(a). The compound was administered to ... (IBV). The data from the study indicated,that QR448(a) ...
Cached Medicine Technology:Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 3Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5
(Date:5/3/2015)... (PRWEB) May 03, 2015 Looking ... that will directly impact your career? The Master ... for dynamic leaders in multinational companies and for ... In a changing global landscape, differences in culture, ... relationships. The EMIB program develops the global competence ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured on NewsWatch ... the latest and coolest technology products available to consumers. ... NewsWatch, conducted the review and shared with viewers how ... is an important part of people’s lives – and ... royal treatment. Peachtree Audio does just that with high-end ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... hotel-style room service to massage therapy to magnificent views, ... bid to gain market share, especially those in competitive ... the New England Journal of Medicine , raises ... care, explaining that how we decide to value the ...
... fatal brain conditions such as mad cow disease in ... the horizon, according to a new study from National ... of Allergy and Infectious Diseases (NIAID) have developed a ... measure infectious agents called prions that cause these diseases. ...
... Healthcare has produced the first results in humans of a ... aggressiveness of prostate tumors in real time, by imaging the ... used this technology to conduct real-time metabolic imaging in human ... outlines of a tumor, its response to treatment and how ...
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... that measures the circuitry of brain connections may someday be ... McLean Hospital in Boston and the University of Utah used ... the brain circuitry in 30 males aged 8 to 26 ...
... crucial for regulating the self-renewal of normal prostate stem ... cells killed by hormone withdrawal therapy for cancer, also ... cells, researchers at UCLA have found. The findings, ... of Regenerative Medicine and Stem Cell Research at UCLA, ...
... inaugural James W. Varnum National Quality Award was presented ... Medical Center (CCHMC), in a ceremony held on Wednesday, ... Hampshire. , Receiving the award were Project SEARCH ... Disability Services; and Dr. Linda Workman, Vice President of ...
Cached Medicine News:Health News:Hospital perks: How much should hospitals be rewarded for the patient experience? 2Health News:NIH study suggests that early detection is possible for prion diseases 2Health News:NIH study suggests that early detection is possible for prion diseases 3Health News:'Watchful waiting' has a new set of eyes 2Health News:'Watchful waiting' has a new set of eyes 3Health News:'Watchful waiting' has a new set of eyes 4Health News:Brain Scan Might Someday Spot Autism 2Health News:Brain Scan Might Someday Spot Autism 3Health News:UCLA scientists discover mechanism that turns healthy cells into prostate cancer cells 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 3
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: